MGNX I don’t think MGD013 alone was the reason for the run today. You missed 2 other important updates:
MGC018 (B7-H3 ADC) In dose escalation, we have also observed early evidence of clinical activity, especially in patients with metastatic castration-resistant prostate cancer, or mCRPC, with reductions in PSA levels of 50% or more in five of seven patients treated including one with sustained regression of bone disease.
The dose escalation is still ongoing. These were actually at lower doses and on previous calls I had indicated, we were very encouraged by the data we're seeing, even in this lower doses range. So we're actually moved the dose up.
MGD019 (PD-1 x CTLA-4 bispecific) We are currently enrolling patients in additional dose escalation cohorts with no dose limiting toxicities observed. Of the 13 of valuable patients treated at doses of three milligrams per kilogram (3mg/kg) or greater, we have observed four patients across different tumor types with three confirmed and one unconfirmed objective response.
But one of the big goals for the 019 study was to achieve the synergy that one sees for combining an anti-PD-1 with anti-CTLA4 without getting the toxicity that has been previously observed with if you need both combination.
Market Data 
Markets 
AI
